公开(公告)号：US20180134696A1

公开(公告)日：2018-05-17

申请号：US15736235

申请日：2016-06-09

申请人： FORUM PHARMACEUTICALS, INC.

发明人： Raksha Acharya ,  Duane A. Burnett ,  Matthew Gregory Bursavich ,  Andrew Simon Cook ,  Bryce Alden Harrison ,  Andrew J. McRiner

IPC分类号： C07D453/02 ,  A61P25/00

CPC分类号： C07D453/02 ,  A61P25/00

摘要： The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

公开(公告)号：US20170247393A1

公开(公告)日：2017-08-31

申请号：US15291740

申请日：2016-10-12

申请人： Forum Pharmaceuticals, Inc.

发明人： Raksha Acharya ,  Duane A. Burnett ,  Matthew Gregory Bursavich ,  Andrew Simon Cook ,  Bryce Alden Harrison ,  Andrew J. McRiner

IPC分类号： C07D498/20 ,  C07D519/00

CPC分类号： C07D498/20 ,  C07D519/00

摘要： The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

公开(公告)号：US20170044182A1

公开(公告)日：2017-02-16

申请号：US15210927

申请日：2016-07-15

申请人： FORUM Pharmaceuticals Inc.

发明人： Duane A. Burnett ,  Matthew Gregory Bursavich ,  Andrew J. McRiner

IPC分类号： C07D498/04 ,  C07D498/20 ,  C07D498/14 ,  C07D498/10

CPC分类号： C07D498/04 ,  C07D498/10 ,  C07D498/14 ,  C07D498/20

摘要： The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

摘要翻译： 本公开内容涉及融合的吗啉代嘧啶，包含有效量的熔融吗啉代嘧啶的药物组合物和使用融合的吗啉代嘧啶治疗神经变性疾病的方法，其包括向有需要的受试者施用有效量的融合的吗啉代嘧啶。

公开(公告)号：US20160137638A1

公开(公告)日：2016-05-19

申请号：US15002163

申请日：2016-01-20

申请人： Forum Pharmaceuticals, Inc.

发明人： Patricia Oliver-Shaffer ,  Gideon Shapiro ,  Richard Chesworth ,  Muneki Kishida ,  Takayuki Ishige

IPC分类号： C07D453/02 ,  A61K31/439 ,  C30B29/54 ,  A61K9/48

CPC分类号： C07D453/02 ,  A61K9/4833 ,  A61K31/439 ,  C07B2200/13 ,  C30B29/54

摘要： Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.

摘要翻译： （R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺盐酸盐一水合物的结晶形式I和II及其制备方法及其治疗用途。

公开(公告)号：US20150274706A1

公开(公告)日：2015-10-01

申请号：US14529435

申请日：2014-10-31

申请人： FORUM Pharmaceuticals Inc.

发明人： Richard CHESWORTH ,  Amy RIPKA ,  Gideon SHAPIRO

IPC分类号： C07D405/14 ,  C07D487/04 ,  C07D405/04

CPC分类号： A61K31/53 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

摘要翻译： 描述了作为磷酸二酯酶10抑制剂的1,2-二取代杂环化合物。 还描述了化合物在治疗哺乳动物（包括中枢神经系统（CNS）病症的人）和可能影响CNS功能的其它疾病中的方法，药物组合物，药物制剂和药物用途。 可以治疗的疾病包括神经学，神经变性和精神病学障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。

公开(公告)号：US08933074B2

公开(公告)日：2015-01-13

申请号：US13919320

申请日：2013-06-17

申请人： FORUM Pharmaceuticals Inc.

发明人： Amy Ripka ,  Gideon Shapiro ,  Richard Chesworth

IPC分类号： A61K31/5377 ,  A61K31/4709 ,  C07D413/14 ,  C07D417/14 ,  C07D405/12 ,  C07D405/14 ,  C07D401/12 ,  C07D401/14 ,  C07D401/04

CPC分类号： A61K31/53 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

摘要翻译： 描述了作为磷酸二酯酶10抑制剂的1,2-二取代杂环化合物。 还描述了化合物在治疗哺乳动物（包括中枢神经系统（CNS）病症的人）和可能影响CNS功能的其它疾病中的方法，药物组合物，药物制剂和药物用途。 可以治疗的疾病包括神经学，神经变性和精神病学障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。

公开(公告)号：US10428062B2

公开(公告)日：2019-10-01

申请号：US15233664

申请日：2016-08-10

申请人： Forum Pharmaceuticals, Inc.

发明人： Raksha Acharya ,  Duane A. Burnett ,  Matthew Gregory Bursavich ,  Andrew Simon Cook ,  Bryce Alden Harrison ,  Andrew J. McRiner

IPC分类号： C07D453/02 ,  C07D453/00 ,  A61P25/00

摘要： The present invention relates to novel geminal substituted aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

公开(公告)号：US20170066753A1

公开(公告)日：2017-03-09

申请号：US15178626

申请日：2016-06-10

申请人： FORUM Pharmaceuticals Inc.

发明人： Raksha Acharya ,  Duane A. Burnett ,  Matthew Gregory Bursavich ,  Andrew Simon Cook ,  Bryce Alden Harrison ,  Andrew J. McRiner

IPC分类号： C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D413/04

CPC分类号： C07D413/14 ,  A61K31/535 ,  C07D247/02 ,  C07D271/02 ,  C07D273/02 ,  C07D273/04 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04

摘要： The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

公开(公告)号：US09550767B2

公开(公告)日：2017-01-24

申请号：US15002163

申请日：2016-01-20

申请人： Forum Pharmaceuticals, Inc.

发明人： Patricia Oliver-Shaffer ,  Gideon Shapiro ,  Richard Chesworth ,  Muneki Kishida ,  Takayuki Ishige

IPC分类号： C07D453/02 ,  A61K9/48 ,  A61K31/439 ,  C30B29/54

CPC分类号： C07D453/02 ,  A61K9/4833 ,  A61K31/439 ,  C07B2200/13 ,  C30B29/54

摘要： Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.

摘要翻译： （R）-7-氯-N-（奎宁环-3-基）苯并[b]噻吩-2-甲酰胺盐酸盐一水合物的结晶形式I和II及其制备方法及其治疗用途。

公开(公告)号：US20160002250A1

公开(公告)日：2016-01-07

申请号：US14851250

申请日：2015-09-11

申请人： FORUM Pharmaceuticals Inc.

发明人： Patricia OLIVER

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  C07B2200/13

摘要： Disclosed are novel crystalline polymorphic forms of 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one and salts thereof, methods of preparing the crystalline polymorphic forms and salts thereof, pharmaceutical compositions comprising the crystalline polymorphic forms and salts thereof, and methods of treating CNS disorders, eating disorders, obesity, compulsive gambling, sexual disorders, narcolepsy, sleep disorders, diabetes, metabolic syndrome, schizophrenia, schizo-affective conditions, Huntington's disease, bipolar disorders, dystonic conditions and tardive dyskinesia, or for use in smoking cessation treatment in a patient using the crystalline polymorphic forms and salts thereof.

摘要翻译： 公开了4-（4-（咪唑并[1,2-b]哒嗪-2-基甲氧基）苯基）-2,2-二甲基-5-（吡啶-4-基）呋喃-3（2H ）及其盐，制备结晶多晶型物及其盐的方法，包含结晶多晶型物及其盐的药物组合物和治疗CNS障碍，进食障碍，肥胖症，强迫性赌博，性障碍，发作性睡眠，睡眠的方法 疾病，糖尿病，代谢综合征，精神分裂症，分裂症情况，亨廷顿舞蹈病，双相情感障碍，肌张力障碍症状和迟发性运动障碍，或用于使用结晶多晶型及其盐的患者戒烟治疗。